Silver Book Fact

Gene transfer process treatment for diabetic retinopathy

A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.

Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski M, et al. Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability. Invest Opthalmol Vis Sci. 2011; 52(12): 8944-8950. http://www.researchgate.net/publication/51720075_Vasoinhibin_Gene_Transfer_by_Adenoassociated_Virus_Type_2_Protects_against_VEGF-_and_Diabetes-Induced_Retinal_Vasopermeability

Reference

Title
Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski M, et al
Volume & Issue
Volume 52, Issue 12
Pages
8944-8950
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Blood Pressure Control in Patients with Diabetes
    Tight blood pressure control in type 2 diabetes patients reduced progression of DR by 34% and risk of deterioration by 47% after 9 years.  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.  
  • Impact of a healthy lifestyle on age-related macular degeneration (AMD)
    A study exploring the impact of a healthy lifestyle on age-related macular degeneration (AMD) found that women whose diets were the healthiest (scored on the 2005 Healthy Eating Index) had…  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…